EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 101 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Mom Who Lost Child Donates Breast Milk To Mom With Cancer February 27, 2019 ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... June 5, 2023 Tackling under-representation of Black data scientists in cancer research November 7, 2022 Determining Fluid Requirements March 26, 2021 Load more HOT NEWS What Are Biosimilars in Cancer Treatment? Mental Health Awareness for Health Care Providers Doctors Say Girl Has ‘Vanishing Bones’ That Are Slowly Disappearing From... “Giving something back”: our supporters are the beating heart of what...
